Unpacking the innards of Theranos’s new Zika-detection box


Image Credits:


heranos has had a long 10 months. The company, beset with regulation issues, has faced a Congressional inquiry, possible criminal charges, lawsuits, a recall of test results from the past two years, its main partner Walgreens severing ties, Forbes downgrading its worth from $9 billion to now just under $800 million, and its founder Elizabeth Holmes was formally banned from operating her own laboratories for the next two years.

So it was in this dark night of despair that Holmes told members of the media and the science community she would finally be opening up about Edison, her one-drop blood analysis technology 11 years in the making. Hundreds of scientists lined up at the American Association for Clinical Chemistry this week in the hopes of finally getting a behind-the-scenes look at the secret machine. Instead, they got an introduction to an entirely new product — an all-in-one Zika-detecting tabletop miniLab.

According to Holmes, the miniLab can run a number of automated tests using blood and urine samples, including one she claimed is a first-of-its-kind for detecting Zika. Those tests are then uploaded through a centralized system that can collect samples, process the data and dispense results.

Holmes told audience members that the plan was to fast-track the device through FDA approval under the newly issued emergency use authorization (EUA) for Zika detectors.

It’s a strategic move for the company. Zika has struck fear within the U.S. health community, especially after 14 people in a Miami neighborhood were recently diagnosed with the primarily mosquito-transmitted illness. Zika is often asymptomatic or causes a mild rash, fever and joint pain. But the bigger concern is what the virus can do to pregnant women. Zika has been linked to microencephaly in infants born to mothers with the disease.

However, detection is tough, and with a lack of any commercially available diagnostic tests cleared or approved by the FDA for Zika at the moment, the virus is spreading rapidly throughout many parts of the Western hemisphere. The FDA has said it would be fast-tracking certain Zika detection tools under EUA for that reason — something Theranos clearly hopes to take advantage of.

Will Theranos’s new miniLab be enough to save the company from itself?

Recycling material

Screen Shot 2016-08-04 at 10.52.42 AM

Theranos seems to have pivoted away from a previous lab testing facility model and is moving into field collection via the new miniLab. But according to several clinical lab scientists with whom TechCrunch spoke to, there’s not anything novel about Theranos’s new product — at least nothing detectable from Holmes’s presentation.

“It left a lot of us dissatisfied. It was kind of a letdown,” University of Chicago’s Jerry Yeo said of the new miniLab. “It doesn’t even have the routine immunoassay and didn’t show how sensitive it was.”

Professor of clinical and lab pathology at Weill Cornell Medical College Stephen Master, who was in the audience at Holmes’s presentation along with Yeo, agreed. “It wasn’t like there was anything fundamentally we hadn’t seen before,” he told TechCrunch.

To be fair, Theranos’s previous mishaps likely jaded much of the scientific community before Holmes took to the stage.

But to Master’s point, there are several companies with “lab-on-a-chip” technology, which Theranos maintains is not what its box is, but does have elements of.

Qualcomm’s Tricorder X-Prize searches for similar companies with the idea of revolutionizing healthcare by placing an accessible lab in the field. The organization offers millions of dollars to companies that can come up with automatic non-invasive health diagnostics packaged into a single portable device. The concept is exactly what Theranos wants to do with the miniLab.

Zika bytes

The new product is also not much different than other Zika-detection prototypes out there – some of which are already listed on the FDA’s website.

Zika detection devices actually seemed to be a trend at AACC’s event this week. John McDevitt from the NYU college of dentistry also presented a device that Master thought sounded pretty much exactly like what Theranos proposed.

“I swear his first five minutes were almost identical to Theranos in terms of the box look, in terms of the slides, some of the pieces that were actually inside. It was another integrated analyzer like that,” Master said.

The difference is McDevitt’s programmable bio-nano-chip, which Master referred to, has been peer reviewed – something the miniLab has yet to do but will likely need if it wants FDA approval.

There were other Zika detectors presented at the conference, as well. One promising device was developed in collaboration with MIT, Harvard, University of Toronto and Cornell University.

It’s unclear how likely, given Theranos’s reputation, the FDA will approve its miniLab, even under fear of Zika. We’ve reached out to the FDA but have not heard back.

But we should note Zika is not the first disease Theranos has used to drum up support within the government for its technology. The company sought FDA approval for early Ebola detection last year, devoting a large chunk of time and resources to its test for the highly contagious and deadly disease.

“We stopped everything for Ebola — for the world,” Theranos exec Richard Kovacevich told the New York Times in 2015. But focus on the disease seemed to fizzle out and Theranos moved on, saying FDA approval for the test was no longer something the company was pursuing. Would the same thing happen if it doesn’t get approval under EUA for Zika?

It also seems quite expensive and makes little sense for Theranos, once a lab operation with dozens of testing facilities inside Walgreens, to switch into manufacturing. Yeo, who has looked into similar operations in the past repeated those concerns to us — but the move may be the result of Holmes’ recent ban from operating her own labs.

So what happened to the old tech? Theranos left a room full of skeptical scientists wanting, barely mentioning the data it has likely gathered over the last decade from its technology. TechCrunch reached out to Theranos to ask about its proprietary Edison technology and how much of it was applied to the new miniLab.

“Edison is the name of one early iteration of this technology,” a spokesperson for Theranos told TechCrunch. “The miniLab is the latest iteration of the company’s testing platform and an evolution of Theranos’s technology.”

We were promised hundreds of tests on a single drop of blood and all we got was this box

Theranos’s tabletop lab is not exactly revolutionary; dozens of companies have made miniature lab-testing devices. And though the company told TechCrunch it has not “worked on a lab-on-a-chip system for some time,” this is, essentially, according to all the experts we spoke to, the same idea. Except it’s a box.

The miniLab is composed of parts that collect small samples of blood and urine to automatically process and upload to a centralized system. It doesn’t process hundreds of lab tests on a single drop of blood, as previously promised.

Holmes showed data from 11 tests in her presentation but says it can run up to 40 tests. However, Yeo told us there would need to be several samples of blood and multiple finger pricks to run these tests, not just one drop of blood for dozens of tests — a far cry from Holmes’s story of getting into this business to make blood testing quick, easy and painless.

“The reality was the reason everyone was in that room [at the conference] was because they made these really broad claims about what their technology was going to be able to do,” Master said. “The excitement was how in the world are they doing that…Instead what they ended up showing was some of the general performance and classes of tests but they never came close to really addressing those larger capabilities that they had talked about.”.

Screen Shot 2016-08-04 at 8.38.29 AM

The key here may be in the automation of lab tests in the field. You’ll see different components in the illustration above of the box from Holmes’ presentation. The founder laid out how her capillary blood collection devices, including the proprietary Nanotainer tubes and Sample Collection Device (SCD) would collect the samples and be inserted into the box to process.

She also outlined the Theranos Virtual Analyzer (TVA), a remote communications software system that could upload results to a lab.

“The miniLab architecture provides a potential framework for testing in a decentralized setting while maintaining centralized oversight,” Holmes told the audience.

Something like that could be applied in the field, like say in a Zika-infested area, but both Master and Yeo emphasized the difficulty in conducting lab testing in an uncontrolled field environment.

“As soon as you start going out into the wild, as it were, into doctor’s offices and different settings, it’s going to be difficult to maintain,” Master said.

It’s also unclear if the miniLab will be fast-tracked to go out into the wild, given the company’s background and current lack of third-party, independent research.

Theranos told TechCrunch it considers its own Zika test as its clinical trial, per FDA guidance. Compare that approach with other device makers like Scanadu, which is in the process of seeking permission from the FDA for its Scout device, partnering with Scripps to conduct a 4,000-person clinical trial to get it there.

However, Holmes did mention during her presentation the company would be publishing the findings from its technology in peer-reviewed journals and conducting third-party studies, indicating Theranos would be subjecting itself to independent scrutiny in the future. But, added Holmes, that “will not happen in one day and one presentation.”

And maybe Theranos is starting to understand how to operate. It’s added a medical advisory board, hired clinical lab experts to key positions, says it wants to be more transparent in the future and, as mentioned, says it is willing to publish in peer-reviewed journals — something it has been roundly criticized for not doing in the past.

Is the box enough to help it regain credibility in the medical community? Who knows. Those in attendance expected to hear about the technology that could produce hundreds of lab tests on a single drop of blood and all it got was this box. From what we’ve gathered the scientific community doesn’t seem overly impressed.

Theranos has an uphill battle ahead to prove itself to these scientists, government regulators and consumers. But one thing is clear, past the jargon and pomp, Theranos is more of an evolution, not a revolution so far.

More TechCrunch

After Apple loosened its App Store guidelines to permit game emulators, the retro game emulator Delta — an app 10 years in the making — hit the top of the…

Adobe comes after indie game emulator Delta for copying its logo

Meta is once again taking on its competitors by developing a feature that borrows concepts from others — in this case, BeReal and Snapchat. The company is developing a feature…

Meta’s latest experiment borrows from BeReal’s and Snapchat’s core ideas

Welcome to Startups Weekly! We’ve been drowning in AI news this week, with Google’s I/O setting the pace. And Elon Musk rages against the machine.

Startups Weekly: It’s the dawning of the age of AI — plus,  Musk is raging against the machine

IndieBio’s Bay Area incubator is about to debut its 15th cohort of biotech startups. We took special note of a few, which were making some major, bordering on ludicrous, claims…

IndieBio’s SF incubator lineup is making some wild biotech promises

YouTube TV has announced that its multiview feature for watching four streams at once is now available on Android phones and tablets. The Android launch comes two months after YouTube…

YouTube TV’s ‘multiview’ feature is now available on Android phones and tablets

Featured Article

Two Santa Cruz students uncover security bug that could let millions do their laundry for free

CSC ServiceWorks provides laundry machines to thousands of residential homes and universities, but the company ignored requests to fix a security bug.

15 hours ago
Two Santa Cruz students uncover security bug that could let millions do their laundry for free

OpenAI’s Superalignment team, responsible for developing ways to govern and steer “superintelligent” AI systems, was promised 20% of the company’s compute resources, according to a person from that team. But…

OpenAI created a team to control ‘superintelligent’ AI — then let it wither, source says

TechCrunch Disrupt 2024 is just around the corner, and the buzz is palpable. But what if we told you there’s a chance for you to not just attend, but also…

Harness the TechCrunch Effect: Host a Side Event at Disrupt 2024

Decks are all about telling a compelling story and Goodcarbon does a good job on that front. But there’s important information missing too.

Pitch Deck Teardown: Goodcarbon’s $5.5M seed deck

Slack is making it difficult for its customers if they want the company to stop using its data for model training.

Slack under attack over sneaky AI training policy

A Texas-based company that provides health insurance and benefit plans disclosed a data breach affecting almost 2.5 million people, some of whom had their Social Security number stolen. WebTPA said…

Healthcare company WebTPA discloses breach affecting 2.5 million people

Featured Article

Microsoft dodges UK antitrust scrutiny over its Mistral AI stake

Microsoft won’t be facing antitrust scrutiny in the U.K. over its recent investment into French AI startup Mistral AI.

17 hours ago
Microsoft dodges UK antitrust scrutiny over its Mistral AI stake

Ember has partnered with HSBC in the U.K. so that the bank’s business customers can access Ember’s services from their online accounts.

Embedded finance is still trendy as accounting automation startup Ember partners with HSBC UK

Kudos uses AI to figure out consumer spending habits so it can then provide more personalized financial advice, like maximizing rewards and utilizing credit effectively.

Kudos lands $10M for an AI smart wallet that picks the best credit card for purchases

The EU’s warning comes after Microsoft failed to respond to a legally binding request for information that focused on its generative AI tools.

EU warns Microsoft it could be fined billions over missing GenAI risk info

The prospects for troubled banking-as-a-service startup Synapse have gone from bad to worse this week after a United States Trustee filed an emergency motion on Wednesday.  The trustee is asking…

A US Trustee wants troubled fintech Synapse to be liquidated via Chapter 7 bankruptcy, cites ‘gross mismanagement’

U.K.-based Seraphim Space is spinning up its 13th accelerator program, with nine participating companies working on a range of tech from propulsion to in-space manufacturing and space situational awareness. The…

Seraphim’s latest space accelerator welcomes nine companies

OpenAI has reached a deal with Reddit to use the social news site’s data for training AI models. In a blog post on OpenAI’s press relations site, the company said…

OpenAI inks deal to train AI on Reddit data

X users will now be able to discover posts from new Communities that are trending directly from an Explore tab within the section.

X pushes more users to Communities

For Mark Zuckerberg’s 40th birthday, his wife got him a photoshoot. Zuckerberg gives the camera a sly smile as he sits amid a carefully crafted re-creation of his childhood bedroom.…

Mark Zuckerberg’s makeover: Midlife crisis or carefully crafted rebrand?

Strava announced a slew of features, including AI to weed out leaderboard cheats, a new ‘family’ subscription plan, dark mode and more.

Strava taps AI to weed out leaderboard cheats, unveils ‘family’ plan, dark mode and more

We all fall down sometimes. Astronauts are no exception. You need to be in peak physical condition for space travel, but bulky space suits and lower gravity levels can be…

Astronauts fall over. Robotic limbs can help them back up.

Microsoft will launch its custom Cobalt 100 chips to customers as a public preview at its Build conference next week, TechCrunch has learned. In an analyst briefing ahead of Build,…

Microsoft’s custom Cobalt chips will come to Azure next week

What a wild week for transportation news! It was a smorgasbord of news that seemed to touch every sector and theme in transportation.

Tesla keeps cutting jobs and the feds probe Waymo

Sony Music Group has sent letters to more than 700 tech companies and music streaming services to warn them not to use its music to train AI without explicit permission.…

Sony Music warns tech companies over ‘unauthorized’ use of its content to train AI

Winston Chi, Butter’s founder and CEO, told TechCrunch that “most parties, including our investors and us, are making money” from the exit.

GrubMarket buys Butter to give its food distribution tech an AI boost

The investor lawsuit is related to Bolt securing a $30 million personal loan to Ryan Breslow, which was later defaulted on.

Bolt founder Ryan Breslow wants to settle an investor lawsuit by returning $37 million worth of shares

Meta, the parent company of Facebook, launched an enterprise version of the prominent social network in 2015. It always seemed like a stretch for a company built on a consumer…

With the end of Workplace, it’s fair to wonder if Meta was ever serious about the enterprise

X, formerly Twitter, turned TweetDeck into X Pro and pushed it behind a paywall. But there is a new column-based social media tool in town, and it’s from Instagram Threads.…

Meta Threads is testing pinned columns on the web, similar to the old TweetDeck

As part of 2024’s Accessibility Awareness Day, Google is showing off some updates to Android that should be useful to folks with mobility or vision impairments. Project Gameface allows gamers…

Google expands hands-free and eyes-free interfaces on Android